[1]
N. SGHERZA, “Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients”, Mediterr J Hematol Infect Dis, vol. 14, no. 1, p. e2022056, Jun. 2022.